These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27570091)

  • 1. Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works.
    Inoue S; Okiyama N; Okune M; Shiraki N; Kessoku R; Fujimoto M
    J Dermatol; 2017 Jan; 44(1):84-87. PubMed ID: 27570091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary management of essential thrombocythemia in children.
    Randi ML; Bertozzi I; Putti MC
    Expert Rev Hematol; 2019 May; 12(5):367-373. PubMed ID: 30925843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
    Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
    Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE
    Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
    Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
    Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential thrombocythaemia with mutation in
    Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
    J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential thrombocythemia presenting as localized livedo reticularis.
    Pielasinski U; Haro R; Santonja C; Kutzner H; Requena L
    Am J Dermatopathol; 2013 Apr; 35(2):e22-5. PubMed ID: 23542719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2
    Saki N; Shirzad R; Rahim F; Saki Malehi A
    Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anagrelide and Mutational Status in Essential Thrombocythemia.
    Iurlo A; Cattaneo D; Orofino N; Bucelli C; Fabris S; Cortelezzi A
    BioDrugs; 2016 Jun; 30(3):219-23. PubMed ID: 27041108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
    Mela Osorio MJ; Ferrari L; Goette NP; Gutierrez MI; Glembotsky AC; Maldonado AC; Lev PR; Alvarez C; Korin L; Marta RF; Molinas FC; Heller PG
    Eur J Haematol; 2016 Apr; 96(4):435-42. PubMed ID: 26119186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two faces of ET: CALR and JAK2.
    Chao MP; Gotlib J
    Blood; 2014 Mar; 123(10):1438-40. PubMed ID: 24627549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
    Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
    Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.
    Dua V; Yadav SP; Kumar V; Saxena R; Sachdeva A
    Int J Hematol; 2012 Dec; 96(6):810-3. PubMed ID: 23054653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
    Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
    Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.